New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell ...

An expert discusses emerging frontline treatments for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting the ...

Innovative treatments like JAK2 inhibitors and bispecific antibodies show promise in overcoming immunotherapy resistance in non-small cell lung cancer.

Welcome to this week's edition of The Targeted Pulse. This week in oncology, we saw a number of significant developments, ...

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...

Berry and colleagues from the Institute for Healthcare Improvement and Henry Ford Health Detroit argue that deep, ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...

Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...

Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...